Philadelphia chromosome-positive acute lymphoblastic leukaemia
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1
The phase 3 results show improvements in daily function, cognition and nighttime sleep
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
FDA unveils new voucher programme to accelerate drug review process
The programme is designed to reduce the review time for companies supporting US national interests
Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma
Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP
The enzyme replacement therapy is now the first treatment approved in the UK for this patient population
Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma
The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication
Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma
Around 800 people in the UK are diagnosed with late-stage disease every year
Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer
Up to 160,000 people in the US are affected by polycythaemia vera
FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years
The mosquito-borne viral disease has been reported across many popular travel destinations
Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy
The progressive neuromuscular disease affects approximately one in every 10,000 babies globally